HSK40118 / Haisco - LARVOL DELTA

TY-2719, a potent and selective broad-spectrum mutation-effective EGFR-PROTAC molecule, attenuates acquired resistance to 3rd-generation EGFR TKIs (AACR 2025) - P1 | "These included CFT8919 (NCT06641609), HSK40118 (NCT06050980), and HJ-002-03 (CTR20241691). TY-2719 did not suppress the growth of normal cells, such as NHEK, and NSCLC cells, such as A549 and A431 cells harboring wild-type EGFR. However, TY-2719 has excellent in vitro antiproliferative activity against a number of EGFR mutants, including common mutations, post osimertinib-resistant mutations, and rare mutations. Our data suggest that TY-2719 has superior selective activity in cells containing EGFR mutants compared to wild-type EGFR-expressing cells."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CRBN • GSPT1 • IKZF1

Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation (clinicaltrials.gov) - P1 | N=220 | Recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd.

Metastases • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor

Haisco (002653.SZ): New Drug Application for Innovative Drug HSK40118 Tablets Accepted [Google translation] (Zhitong Finance) - "Zhitong Finance APP News, Haisco... announced that the company recently received the 'Notice of Acceptance' issued by the State Drug Administration for 'HSK40118 Tablets', and after review, it was decided to accept it."

Non-US regulatory • Lung Cancer • Non Small Cell Lung Cancer • Oncology

Sichuan Haisco Pharmaceutical describes new PROTACs for NSCLC (Bioworld) - "Sichuan Haisco Pharmaceutical Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently bonded to an EGFR (HER1; erbB1) targeting moiety through a linker reported to be useful for the treatment of non-small-cell lung cancer (NSCLC)."

New molecule • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor